炎症性肠病（IBD）的新型疗法与方法
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).
作者信息
Furfaro Federica, Ragaini Elisa, Peyrin-Biroulet Laurent, Danese Silvio
机构信息
Department of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, 20132 Milan, Italy.
Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy.
出版信息
J Clin Med. 2022 Jul 28;11(15):4374. doi: 10.3390/jcm11154374.
Abstract
Inflammatory bowel diseases (IBDs), divided into two predominant groups, Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing inflammatory diseases of the gastrointestinal tract, resulting from an aberrant immune response to microbes in the gut, in genetically susceptible patients [...].
摘要
炎症性肠病（IBDs）分为两个主要类型，即克罗恩病（CD）和溃疡性结肠炎（UC），是胃肠道的慢性复发性炎症性疾病，由基因易感患者肠道内对微生物的异常免疫反应引起[...]。
相似文献
1
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).炎症性肠病（IBD）的新型疗法与方法
J Clin Med. 2022 Jul 28;11(15):4374. doi: 10.3390/jcm11154374.
2
Two-Sample Mendelian Randomization Analysis Investigates Causal Associations Between Gut Microbial Genera and Inflammatory Bowel Disease, and Specificity Causal Associations in Ulcerative Colitis or Crohn's Disease.两样本孟德尔随机化分析探究肠道微生物属与炎症性肠病之间的因果关联，以及溃疡性结肠炎或克罗恩病中特定的因果关联。
Front Immunol. 2022 Jul 4;13:921546. doi: 10.3389/fimmu.2022.921546. eCollection 2022.
3
Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.患者对吸烟与炎症性肠病的看法：与欧洲克罗恩病和溃疡性结肠炎协会合作开展的在线调查
World J Gastroenterol. 2020 Aug 7;26(29):4343-4355. doi: 10.3748/wjg.v26.i29.4343.
4
Dysbiosis in the pathogenesis of pediatric inflammatory bowel diseases.儿童炎症性肠病发病机制中的生态失调
Int J Inflam. 2012;2012:687143. doi: 10.1155/2012/687143. Epub 2012 May 20.
5
Dysbiosis and Ecotypes of the Salivary Microbiome Associated With Inflammatory Bowel Diseases and the Assistance in Diagnosis of Diseases Using Oral Bacterial Profiles.与炎症性肠病相关的唾液微生物群失调与生态型以及利用口腔细菌谱辅助疾病诊断
Front Microbiol. 2018 May 30;9:1136. doi: 10.3389/fmicb.2018.01136. eCollection 2018.
6
A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders.肠道中半乳糖凝集素的特征性标志可将克罗恩病和溃疡性结肠炎与其他人类炎症性肠病区分开来。
Biofactors. 2016 Jan-Feb;42(1):93-105. doi: 10.1002/biof.1252. Epub 2016 Feb 1.
7
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.巴西炎症性肠病患者一年的真实世界治疗模式和疾病控制情况。
World J Gastroenterol. 2021 Jun 21;27(23):3396-3412. doi: 10.3748/wjg.v27.i23.3396.
8
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响：直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
9
Inflammatory bowel disease: between genetics and microbiota.炎症性肠病：遗传与微生物组之间。
Mol Biol Rep. 2020 Apr;47(4):3053-3063. doi: 10.1007/s11033-020-05318-5. Epub 2020 Feb 21.
10
The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview.炎症性肠病中的促动力蛋白系统：临床与临床前概述
Biomedicines. 2023 Nov 6;11(11):2985. doi: 10.3390/biomedicines11112985.
引用本文的文献
1
Inorganic dietary nanoparticles in intestinal barrier function of inflammatory bowel disease: allies or adversaries?无机膳食纳米颗粒在炎症性肠病肠道屏障功能中的作用：盟友还是对手？
Front Immunol. 2025 Apr 9;16:1563504. doi: 10.3389/fimmu.2025.1563504. eCollection 2025.
2
SLC6A14 promotes ulcerative colitis progression by facilitating NLRP3 inflammasome-mediated pyroptosis.溶质载体家族6成员14（SLC6A14）通过促进NLRP3炎性小体介导的细胞焦亡来推动溃疡性结肠炎的进展。
World J Gastroenterol. 2024 Jan 21;30(3):252-267. doi: 10.3748/wjg.v30.i3.252.
3
Modern drug discovery for inflammatory bowel disease: The role of computational methods.炎症性肠病的现代药物发现：计算方法的作用。
World J Gastroenterol. 2023 Jan 14;29(2):310-331. doi: 10.3748/wjg.v29.i2.310.
本文引用的文献
1
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
2
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.依特利珠单抗与英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）的随机、双盲、双模拟、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.
3
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
4
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.PTG-100，一种口服 α4β7 拮抗剂肽：在溃疡性结肠炎中的临床前开发和 1 期和 2a 期研究。
Gastroenterology. 2021 Dec;161(6):1853-1864.e10. doi: 10.1053/j.gastro.2021.08.045. Epub 2021 Aug 30.
5
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.抗黏膜地址素细胞黏附分子-1 单克隆抗体 Ontamalimab（SHP647）治疗克罗恩病的长期安全性和疗效：OPERA II 研究。
Inflamm Bowel Dis. 2022 Jul 1;28(7):1034-1044. doi: 10.1093/ibd/izab215.
6
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.Filgotinib 作为溃疡性结肠炎的诱导缓解和维持治疗（SELECTION）：一项 2b/3 期双盲、随机、安慰剂对照试验。
Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3.
7
Novel and Emerging Therapies for Inflammatory Bowel Disease.炎症性肠病的新型和新兴疗法
Front Pharmacol. 2021 Apr 14;12:651415. doi: 10.3389/fphar.2021.651415. eCollection 2021.
8
Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.ABX464用于中重度溃疡性结肠炎的诱导治疗及长期随访：IIa期试验结果
Gastroenterology. 2021 Jun;160(7):2595-2598.e3. doi: 10.1053/j.gastro.2021.02.054. Epub 2021 Mar 2.
9
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.艾曲莫德治疗溃疡性结肠炎的长期安全性和有效性：来自OASIS研究开放标签扩展的结果。
J Crohns Colitis. 2021 Jun 22;15(6):950-959. doi: 10.1093/ecco-jcc/jjab016.
10
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.奥扎莫德诱导疗法治疗中重度克罗恩病患者：单臂、2 期、前瞻性观察者设盲终点研究。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):819-828. doi: 10.1016/S2468-1253(20)30188-6. Epub 2020 Jun 15.
Zotero 插件